Key clinical point: Significant improvement in patient-reported outcomes was observed with filgotinib in patients with rheumatoid arthritis (RA) with an insufficient response to methotrexate or biological disease-modifying antirheumatic drugs (DMARD) and those who were methotrexate-naive.
Major finding: Filgotinib at doses of 200 mg or 100 mg in combination with methotrexate/conventional synthetic DMARDs or 200 mg filgotinib monotherapy demonstrated a significant improvement in the health-related quality of life, fatigue, and assessments of disease activity and work impairment vs. comparators (all P < .05).
Study details: This was a post hoc analysis of phase 3 studies including patients with RA with an inadequate response to methotrexate ( FINCH 1 ) or biological DMARDs ( FINCH 2 ) and those who were methotrexate-naive ( FINCH 3 ).
Disclosures: This study was supported by Gilead Sciences, Inc., Foster City, CA. SJ Lee, L Ye, and H Hu reported being employees and shareholders of Gilead Sciences. All the other authors disclosed receiving grants/research support and speaker/consultancy fees from various companies including Gilead Sciences.
Source: Bingham CO III et al. Arthritis Res Ther. 2022;24:11 (Jan 3). Doi: 10.1186/s13075-021-02677-7.